These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38635903)

  • 1. CD58 Alterations Govern Antitumor Immune Responses by Inducing PDL1 and IDO in Diffuse Large B-Cell Lymphoma.
    Xu X; Zhang Y; Lu Y; Zhang X; Zhao C; Wang J; Guan Q; Feng Y; Gao M; Yu J; Song Z; Liu X; Golchehre Z; Li L; Ren W; Pan-Hammarström Q; Zhang H; Wang X
    Cancer Res; 2024 Jul; 84(13):2123-2140. PubMed ID: 38635903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD2-negative lymphoma-associated T-cells: a potential mechanism of immune-evasion in diffuse large B-cell lymphoma.
    Ghosh A; Marques-Piubelli ML; Wang X; Sheu TG; Cheng J; Khan K; Lu W; Manning J; Tang G; Solis LM; Vega F
    Virchows Arch; 2022 Oct; 481(4):659-663. PubMed ID: 35622145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.
    Zhou XA; Louissaint A; Wenzel A; Yang J; Martinez-Escala ME; Moy AP; Morgan EA; Paxton CN; Hong B; Andersen EF; Guitart J; Behdad A; Cerroni L; Weinstock DM; Choi J
    J Invest Dermatol; 2018 Nov; 138(11):2365-2376. PubMed ID: 29857068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.
    Cao Y; Zhu T; Zhang P; Xiao M; Yi S; Yang Y; Li Q; Ling S; Wang Y; Gao L; Zhu L; Wang J; Wang N; Huang L; Zhang P; Zhai Q; Qiu L; Zhou J
    Oncotarget; 2016 Dec; 7(50):83294-83307. PubMed ID: 27825110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Ninomiya S; Hara T; Tsurumi H; Hoshi M; Kanemura N; Goto N; Kasahara S; Shimizu M; Ito H; Saito K; Hirose Y; Yamada T; Takahashi T; Seishima M; Takami T; Moriwaki H
    Ann Hematol; 2011 Apr; 90(4):409-16. PubMed ID: 20938662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity.
    Ho P; Melms JC; Rogava M; Frangieh CJ; Poźniak J; Shah SB; Walsh Z; Kyrysyuk O; Amin AD; Caprio L; Fullerton BT; Soni RK; Ager CR; Biermann J; Wang Y; Khosravi-Maharlooei M; Zanetti G; Mu M; Fatima H; Moore EK; Vasan N; Bakhoum SF; Reiner SL; Bernatchez C; Sykes M; Mace EM; Wucherpfennig KW; Schadendorf D; Bechter O; Shah P; Schwartz GK; Marine JC; Izar B
    Cancer Cell; 2023 Jul; 41(7):1207-1221.e12. PubMed ID: 37327789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.
    Four M; Cacheux V; Tempier A; Platero D; Fabbro M; Marin G; Leventoux N; Rigau V; Costes-Martineau V; Szablewski V
    Hematol Oncol; 2017 Dec; 35(4):487-496. PubMed ID: 27966264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma.
    Challa-Malladi M; Lieu YK; Califano O; Holmes AB; Bhagat G; Murty VV; Dominguez-Sola D; Pasqualucci L; Dalla-Favera R
    Cancer Cell; 2011 Dec; 20(6):728-40. PubMed ID: 22137796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD58 mutations are common in Hodgkin lymphoma cell lines and loss of CD58 expression in tumor cells occurs in Hodgkin lymphoma patients who relapse.
    Abdul Razak FR; Diepstra A; Visser L; van den Berg A
    Genes Immun; 2016 Sep; 17(6):363-6. PubMed ID: 27467287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IDO inhibitor synergized with radiotherapy to delay tumor growth by reversing T cell exhaustion.
    Liu M; Li Z; Yao W; Zeng X; Wang L; Cheng J; Ma B; Zhang R; Min W; Wang H
    Mol Med Rep; 2020 Jan; 21(1):445-453. PubMed ID: 31746428
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Godfrey J; Tumuluru S; Bao R; Leukam M; Venkataraman G; Phillip J; Fitzpatrick C; McElherne J; MacNabb BW; Orlowski R; Smith SM; Kline J
    Blood; 2019 May; 133(21):2279-2290. PubMed ID: 30910787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of Aberrant CD58 Expression in a Wide Spectrum of Lymphoma Subtypes: Implications for Treatment Resistance.
    Younes S; Zhao S; Bharadwaj S; Mosquera AP; Libert D; Johnsrud A; Majzner RG; Miklos DB; Frank MJ; Natkunam Y
    Mod Pathol; 2023 Oct; 36(10):100256. PubMed ID: 37391168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of co-inhibitory molecules B7-H4 and B7-H1 in Epstein-Barr virus positive diffuse large B-cell lymphoma and their roles in tumor invasion.
    Jiang Y; Lin J; Zhang J; Lu S; Wang C; Tong Y
    Pathol Res Pract; 2019 Dec; 215(12):152684. PubMed ID: 31679792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.
    Xu-Monette ZY; Li J; Xia Y; Crossley B; Bremel RD; Miao Y; Xiao M; Snyder T; Manyam GC; Tan X; Zhang H; Visco C; Tzankov A; Dybkaer K; Bhagat G; Tam W; You H; Hsi ED; van Krieken JH; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; Winter JN; Medeiros JT; Xu B; Li Y; Kirsch I; Young KH
    J Immunother Cancer; 2019 Oct; 7(1):272. PubMed ID: 31640780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Costimulatory Function of Cd58/Cd2 Interaction in Adaptive Humoral Immunity in a Zebrafish Model.
    Shao T; Shi W; Zheng JY; Xu XX; Lin AF; Xiang LX; Shao JZ
    Front Immunol; 2018; 9():1204. PubMed ID: 29904386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Characteristics of Chinese Diffuse Large B-Cell Lymphoma Patients: Implications for Cancer Immunotherapies.
    Xu PP; Sun C; Cao X; Zhao X; Dai HJ; Lu S; Guo JJ; Fu SJ; Liu YX; Li SC; Chen M; McCord R; Venstrom J; Szafer-Glusman E; Punnoose E; Kiermaier A; Cheng G; Zhao WL
    EBioMedicine; 2018 Jul; 33():94-104. PubMed ID: 29936139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.
    Arribas AJ; Gaudio E; Napoli S; Yvon Herbaux CJ; Tarantelli C; Bordone RP; Cascione L; Munz N; Aresu L; Sgrignani J; Rinaldi A; Kwee I; Rossi D; Cavalli A; Zucca E; Stussi G; Stathis A; Sloss C; Davids MS; Bertoni F
    bioRxiv; 2023 Nov; ():. PubMed ID: 38014209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas.
    Pascual M; Mena-Varas M; Robles EF; Garcia-Barchino MJ; Panizo C; Hervas-Stubbs S; Alignani D; Sagardoy A; Martinez-Ferrandis JI; Bunting KL; Meier S; Sagaert X; Bagnara D; Guruceaga E; Blanco O; Celay J; Martínez-Baztan A; Casares N; Lasarte JJ; MacCarthy T; Melnick A; Martinez-Climent JA; Roa S
    Blood; 2019 May; 133(22):2401-2412. PubMed ID: 30975638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.